NLRP3 and metabolic dysfunction-associated steatohepatitis: In recent years, a growing number of studies have confirmed the relationship between NLRP3 and NASH, and blockade of NLRP3 inflammasome activation can reduce liver inflammation and fibrosis as well as improve NASH pathology (Calcagno et al. 2022; Mridha et al. 2017).